Citations

Clear

16 citation(s) found for "Delgado, Jose".

Rheumatoid factor and anticitrullinated protein antibody status jointly influence the association between disease activity and cardiovascular risk in rheumatoid arthritis
Karpouzas, George , González‐Gay, Miguel Á. , Pascual‐Ramos, Virginia , Misra, Durga Prasanna , Rantapää‐Dahlqvist, Solbritt , Sfikakis, Petros , Dessein, Patrick , Hitchon, Carol A, Galarza-Delgado, D. Á. , Riel, Piet Van, Hauge, Ellen M., Kitas, George D, Karpouzas, George Athanasios , Myasoedova, Elena , Rantapää-Dahlqvist, Solbritt , Dessein, Patrick , Galarza-Delgado, Dionicio Angel , Semb, Anne Grete , Gonzalez-Gay, Miguel A , Misra, Durga Prasanna , Myasoedova, Elena , Dessein, Patrick H , Hitchon, Carol , Semb, Anne Grete , Hauge, Ellen‐Margrethe , Ormseth, Sarah R.

Mayo Clinic

RMD Open | June 24, 2026 | Volume: 12 | Issue: 2 | Pages: e006929

10.1136/rmdopen-2026-006929 | PMID 42342284 Get It

Objectives Rheumatoid factor (RF) and anticitrullinated protein antibodies (ACPA) are linked to disease activity, severity and cardiovascular risk in rheumatoid arthritis (RA). Since RA-related inflammation associates with cardiovascular disease, we investigated whether RF and ACPA status influence the relationship between RA activity and event risk. Methods We assessed 3952 cardiovascular disease-free patients with prevalent RA registered in an international observational consortium between 1985 and 2012. Main outcome was a first major adverse cardiovascular event (MACE) including myocardial infarction, stroke and cardiovascular death. Follow-up accrued from enrolment until first MACE or censoring. Multivariable Cox models stratified by centre risk evaluated disease activity, RF, ACPA and their interactions. Results We recorded 184 first MACE events over 22 981 patient-years. Disease activity associated with MACE (HR 1.18 (95% CI 1.03 to 1.35)), whereas RF (HR 1.26 (0.82 to 1.94)) and ACPA (HR 1.25 (0.85 to 1.83)) did not reach statistical significance, though CIs were wide and a clinically meaningful association cannot be excluded. A three-way interaction between disease activity, RF and ACPA on MACE (p for interaction=0.044) was observed. RA activity associated with MACE in seronegative and double seropositive (p≤0.047), but not single RF-positive or ACPA-positive patients. Among RF-negative participants, RA activity was linked to MACE in ACPA-negative but not positive ones (p for interaction=0.003). Among ACPA-positive patients, disease activity was linked to MACE in RF-positive but not RF-negative ones (p for interaction=0.040). Conclusions Disease activity may better discriminate inflammation-driven cardiovascular risk in seronegative and double seropositive than single RF-positive or ACPA-positive patients. Risk protection through lowering disease activity may be serostatus dependent.
Sex and anticitrullinated protein antibodies modify the relationship between inflammation and cardiovascular risk in rheumatoid arthritis
Karpouzas, George , Pascual-Ramos, Gonzalez-Gay, Miguel A, Misra, Durga P, Rantapää-Dahlqvist, Solbritt, Sfikakis, Petros , Dessein, Patrick, Hitchon, C., Galarza-Delgado, D. Á. , Riel, Piet Van, Hauge, Ellen-M., Kitas, George D, González‐Gay, Miguel Á. , Rantapää‐Dahlqvist, Solbritt , Misra, Durga Prasanna , Karpouzas, George Athanasios , Pascual-Ramos, Virginia , Gonzalez-Gay, Miguel A , Misra, Durga Prasanna , Myasoedova, Elena , Rantapää-Dahlqvist, Solbritt , Dessein, Patrick , Galarza-Delgado, Dionicio Angel , Semb, Anne Grete , Hauge, Ellen-M , Pascual‐Ramos, Virginia , Myasoedova, Elena , Dessein, Patrick H , Hitchon, Carol , Semb, Anne Grete , Hauge, Ellen‐Margrethe , Ormseth, Sarah R.

Mayo Clinic

RMD Open | February 2, 2026 | Volume: 12 | Issue: 1 | Pages: e006420

10.1136/rmdopen-2025-006420 | PMID 41629127 Get It

Objectives Female sex and anticitrullinated protein antibodies (ACPA) are associated with higher disease activity in rheumatoid arthritis (RA). Since disease-related inflammation is linked to cardiovascular risk, we explored whether sex and ACPA influenced the association between disease activity at study entry and cardiovascular risk in established RA. Methods We evaluated 4008 patients with prevalent RA from an international observational cohort enrolled between 1985 and 2012. Outcomes included major adverse cardiovascular events (MACE: cardiovascular death, myocardial infarction and stroke) and ischaemic cardiovascular events (iCVE: MACE, angina, revascularisation, transient ischaemic attack and peripheral arterial disease). Follow-up accrued from enrolment until the first event or censoring. Multivariable Cox models stratified by centre risk evaluated disease activity, sex, ACPA and their interactions. Results We documented 193 MACE and 299 iCVE. Disease activity and sex were associated with MACE (all p≤0.017) and iCVE (p≤0.005) but ACPA was only associated with MACE (p=0.043). A three-way interaction on MACE (p=0.034) but not iCVE was noted. Among ACPA-negative patients, disease activity was associated with MACE in males (HR 1.57 (95% CI 1.14 to 2.16)) but not females (p-for-interaction=0.022). Among ACPA-positive patients, neither the disease activity x sex interaction (p=0.929), nor main effect of disease activity on MACE (p=0.124) was significant, but male sex was (HR 1.61 (95% CI 1.15 to 2.27)). Among females, neither disease activity x ACPA interaction (p=0.523) nor disease activity (p=0.319) was significant for MACE, but ACPA was (HR 1.57 (95% CI 1.02 to 2.42)). Conclusions The effect of disease activity at enrolment on cardiovascular risk in prevalent RA varies across patient groups with different sex and ACPA characteristics.
Abstract DP310: Dual Antiplatelet versus Anticoagulant-Plus-Antiplatelet Therapy in Symptomatic Intracranial Atherosclerosis: A Multicenter Comparative Study
Rehman, M. Aemaz Ur, Yaghi, Shadi, Kasab, Sami Al, Qdais, Ahmad Abu, Yaddanapudi, Sridhara , Sultana, Sabiha , Khan, Muhib, Malik, Maarij , Klaas, James P. , Guerrero, Christopher Leon, Velez, Faddi Saleh, Pinto, Camila, McCullough-Hicks, Margy, Cooper, Dawson C , Pillai, Abhiram Parameswaran, Hariharan, Praveen, Alam, Shaista , Antonenko, Kateryna, Almiri, William , Rothstein, Aaron, Krishnaiah, Balaji , Elangovan, Cheran, Agarwal, Ayush, Romoli, Michele, Nicola, Marrone, Vozzi, Stefano, Ghannam, Malik, Dibas, Mahmoud I., Marto, Joao Pedro, AlMajali, Mohammad, Sousa, Diana Aguiar de, Soares, Mafalda Delgado, Lima, Anicléia Rodrigues de, Tountopoulou, Argyro , Havenon, Adam de, Henninger, Nils, Helenius, Johanna, Khasawneh, Mohammad W , Klein, Piers, Shu, Liqi , Khatri, Pooja, Nguyen, Thanh N., Liebeskind, D, Bakradze, Ekaterina, Henninger, Nils , Sousa, Diana Aguiar de , Henninger, Nils , Aguiar de Sousa, Diana , Khan, Fahad , Yaghi, Shadi , Kasab, Sami Al , Sultana, Sabiha, Khan, Muhib , Leon Guerrero, Christopher R , Velez, Faddi G. Saleh , Owens, Cameron , Pinto, Camila, McCullough‐Hicks, Margy , Hariharan, Praveen , Alam, Shaista, Heldner, Mirjam R. , Antonenko, Kateryna , Rothstein, Aaron , Elangovan, Cheran , Romoli, Michele , Marrone, Nicola , Ghannam, Malik , Dibas, Mahmoud, Marto, João Pedro , Simpkins, Alexis N. , Soares, Mafalda , Lima, Amanda, Siegler, James E. , VASILOPOULOU, SOFIA, Klein, Piers , Bakradze, Ekaterina

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: Suppl_1 | Pages: No page available

10.1161/str.57.suppl_1.dp310 Get It

Introduction: Intracranial atherosclerosis (ICAS) is a leading cause of ischemic stroke (IS) worldwide and carries a high risk of recurrence. Current guidelines favor 90 days of dual antiplatelet therapy (DAPT) for severe symptomatic ICAS, but recurrence remain high. Limited data suggest possible benefit of single antiplatelet plus anticoagulation (SAPT+AC). We compared the effectiveness and safety of DAPT versus SAPT+AC. We hypothesized that DAPT would lower 90-day recurrent IS risk without significantly increasing bleeding. Methods: This substudy of the Biomarkers and Recurrence Risk in Symptomatic Intracranial Arterial Stenosis (BIORISK-ICAS) included patients from 35 centers (Jan 2019–Jun 2024) with symptomatic 50–99% ICAS in the intracranial internal carotid, vertebral, basilar, or M1 segment of the MCA, presenting ≤72 hours from last known well. The primary efficacy outcome was recurrent IS in the same vascular territory at 90 days; the primary safety outcome was severe bleeding (symptomatic intracranial hemorrhage or major extracranial bleeding). Categorical variables were compared using χ 2 and continuous variables with the Student's t test; multivariable Cox regression adjusted for key covariates. Results: Of 2050 BIORISK-ICAS patients, 1658 met criteria (DAPT n=1499; SAPT+AC n=159). Mean age was 67 vs. 73 years, and 44% were women. At 90 days, recurrent IS occurred in 121 DAPT patients (8.07%) vs. 13 SAPT+AC patients (8.17%); unadjusted HR 0.83 (95% CI, 0.50–1.36; p=0.46). After adjustment for age, diabetes, coronary heart disease, atrial fibrillation, active smoking, and borderzone infarct, the adjusted HR was 0.99 (95% CI, 0.52–1.86; p=0.97). Severe bleeding occurred in 34 DAPT patients (2.26%) and 5 SAPT+AC patients (3.14%); unadjusted HR 0.79 (95% CI, 0.28–1.85; p=0.50), adjusted HR 0.66 (95% CI, 0.21–2.09; p=0.47). Conclusions: In patients with symptomatic ICAS, DAPT and SAPT+AC were associated with similar risks of 90-day recurrent ischemic stroke and severe bleeding. Well-powered randomized trials are needed to determine the optimal antithrombotic regimen in this high-risk population.
Characteristics of patients with extracranial cervical artery dissections involving more than a single vessels: A subgroup analysis of STOP-CAD
Metanis, Issa, Akpokiere, Favour , Shu, Liqi , Jubran, Hamza , Antonenko, Kateryna, Rosa, Sara, Soares, Mafalda Delgado, Engelter, Stefan T. , Traenka, Christopher Kenan, Marto, João Pedro, Romoli, Michele, Zubair, Adeel , Omran, Setareh Salehi , Jubeh, Tamer , Shalabi, Fatma , Khan, Muhib, DeSousa, Diana Aguiar, Yaghi, Shadi, Leker, Ronen R., Sousa, Diana Aguiar de , Soares, Mafalda , Rosa, Sara , Jubran, Hamza , Engelter, Stefan T , Kaufman, Josefin E , Marto, João Pedro , Keser, Zafer , Aguiar de Sousa, Diana , Leker, Ronen R , Soares, Mafalda , Rosa, Sara , Metanis, Issa , Schwartzmann, Yoel , Antonenko, Kateryna , Heldner, Mirjam R. , Kaufmann, Josefin E. , Romoli, Michele , Keser, Zafer , Khan, Muhib , Yaghi, Shadi

Mayo Clinic

European Stroke Journal | January 20, 2026 | Volume: 11 | Issue: 1 | Pages: No page available

10.1093/esj/23969873251383313 | PMID 41614464 Get It

Abstract Introduction Cervical arterial dissections (CeAD) can involve either single (sCeAD) or multiple (mCeAD) arteries. Whether the involvement of a single versus multiple arteries is associated with outcomes remains unclear. We aimed to study associations between the number of affected arteries and clinical, imaging and outcome parameters. Patients and methods Patients with CeAD from the STOP-CAD multicenter registry study were included. Clinical, imaging, treatment and outcome parameters were compared between patients with sCeAD and mCeAD. Regression analyses were performed to identify associations with multi-arteries involvement. Results Overall, 3858 STOP-CAD patients were included in this analysis and 443 (11.5%) had mCeAD. The presence of mCeAD was associated with age (adjusted odds ratio [aOR] 95% confidence intervals [95% CI] 0.99; (0.98–1.00)), female sex (aOR 1.5; 95% CI 1.17–1.91), recent upper respiratory infection (aOR 2.25; 95% CI 1.55–3.27), presence of connective tissue disease (aOR 3.11; 95% CI 2.32–4.17), severe arterial stenosis (aOR 1.95; 95% CI 1.95–2.58), intracranial extension (aOR 1.47; 95% CI 1.04–2.09), vertebral artery involvement (aOR 2.50; 95% CI 1.94–3.22) and presence of dissecting aneurysm (aOR 2.59; 95% CI 1.95–3.42). In adjusted analyses, mCeAD was not associated with clinical outcomes (ischemic stroke, mortality, and sICH; all p > 0.05). Conclusions mCeAD does not appear to increase risk of subsequent stroke as compared to sCAD despite baseline risk factors suggestive of vasculopathy. mCeAD patients who did develop a stroke presented with milder strokes and less often had vessel occlusions compared to those with sCeAD. The presence of mCeAD did not impact outcomes.
Recurrent Cervical Artery Dissection Prevalence and Predictors: A Secondary Analysis of the STOP-CAD Study
Marto, João Pedro, Shu, Liqi , Wu, Eileen , Mendel, Daniel M., Heldner, Mirjam R. , Kaufmann, Josefin E. , Leker, Ronen R., Zedde, Marialuisa, Nehme, Ahmad , Muppa, Jayachandra , Sousa, Diana Aguiar de, Sousa, João André, Fonseca, Ana Catarina , Nzwalo, Hipólito , Romoli, Michele, Omran, Setareh Salehi , Keser, Z, Kam, Wayneho , Zubair, Adeel , Velez, Faddi G. Saleh, Elangovan, Cheran, Krishnaiah, Balaji , Metanis, Issa, Siegler, James E., Rothstein, Aaron, Khazaal, Ossama , Antonenko, Kateryna, Lester, Evan, Crandall, Ross , Rosa, Sara, Soares, Mafalda Delgado, Bakradze, Ekaterina, Ghannam, Malik , Elnazeir, Marwa , Klein, Piers, Traenka, Christopher , Henninger, Nils, Nguyen, Thanh N., Yaghi, Shadi, Zedde, Marialuisa , Henninger, Nils , Marto, João Pedro , Mandel, Daniel , Sousa, Diana Aguiar de , Soares, Mafalda , Marto, João Pedro , Wu, Eileen , Mandel, Daniel M , Leker, Ronen R , Zedde, Marialuisa , Aguiar de Sousa, Diana , Sousa, Joao Andre , Romoli, Michele , Salehi Omran, Setareh , Keser, Zafer , Bavarsad Shahripour, Reza , Kam, Wayneho , Zubair, Adeel , Saleh Velez, Faddi , Elangovan, Cheran , Krishnaiah, Balaji , Metanis, Issa , Pascarella, Rosario , Siegler, James E , Rothstein, Aaron , Khazaal, Ossama , Antonenko, Kateryna , Simpkins, Alexis N , Crandall, Ross , Rosa, Sara , Soares, Mafalda , Bakradze, Ekaterina , Willey, Joshua , Ghannam, Malik , Samaniego, Edgar A , Elnazeir, Marwa , Klein, Piers , Traenka, Christopher , Henninger, Nils , Nguyen, Thanh N , Engelter, Stefan T , Yaghi, Shadi , Muppa, Jayachandra , Heldner, Mirjam R , Kaufman, Josefin E , Fonseca, Ana Catarina , Nzwalo, Hipolito , Nehme, Ahmad , Keser, Zafer , Shahripour, Reza Bavarsad , Velez, Faddi G. Saleh , Elangovan, Cheran , Metanis, Issa , Pascarella, Rosario , Siegler, James E. , Rothstein, Aaron , Simpkins, Alexis N. , Bakradze, Ekaterina , Klein, Piers , Nguyen, Thanh N. , Engelter, Stefan T. , Yaghi, Shadi

Mayo Clinic

Stroke | January 12, 2026 | Volume: 57 | Issue: 4 | Pages: 876-882

10.1161/strokeaha.125.053299 | PMID 41521918 Get It

BACKGROUND: Patients with cervical artery dissection (CeAD) may experience a recurrent dissection, but its frequency, risk factors, and clinical implications are not well defined. We aimed to determine the risk, associated factors, and clinical impact of recurrent CeAD. METHODS: The STOP-CAD study (Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection) was a multicenter international retrospective observational study of patients with CeAD treated between January 2015 and June 2022. Recurrent dissection was defined as a CeAD occurring at least 7 days after the diagnosis of the index event that affects a different artery or a different segment of the same artery. Patients were followed from day 7 up to 2 years. The absolute risk of recurrent CeAD over time was calculated using Kaplan-Meier survival estimates. Multivariable logistic and Cox regression models were used to assess predictors of CeAD recurrence. RESULTS: Of the 4023 patients included in STOP-CAD, 3836 (median age 46 years, 45% women) were eligible for this analysis. During a median (interquartile range) follow-up of 295 (97–720) days, 88 (2.29%) patients had a CeAD recurrence. Median time-to-recurrent CeAD was 53 (interquartile range, 18–157) days. The estimated risk of recurrent CeAD at 2 years was 3.22% (95% CI, 2.59%–4.00%). In multivariable analyses, younger age (adjusted odds ratios, 0.98 [95% CI, 0.96–0.99]), migraine (adjusted odds ratio, 1.88 [95% CI, 1.14–3.07]), and fibromuscular dysplasia (adjusted odds ratio, 2.90 [95% CI, 1.66–5.06]) were associated with CeAD recurrence, while presenting with an ischemic stroke was associated with a lower likelihood of recurrence (adjusted odds ratio, 0.47 [95% CI, 0.29–0.75]). These associations with CeAD recurrence over time were confirmed by Cox regression analyses. Among the 88 patients with recurrent CeAD, only 5 had accompanying ischemic events (3 strokes, 2 transient ischemic attacks). CONCLUSIONS: In this retrospective study, recurrent CeAD was uncommon, approximately half of the events were diagnosed within the first 2 months of the index event, and recurrent events rarely caused new ischemic events. Younger age, migraine, absence of ischemic stroke at presentation, and signs of fibromuscular dysplasia may help identify high-risk patients.
Novel Percutaneous Management of Giant Vegetations With Pulmonary Emboli
Delgado, J. Fernández , Khazen, César , Carrillo, Roger G. , Moreno, Jose Delgado , Khazen, Cesar

Mayo Clinic

Journal of Cardiovascular Electrophysiology | November 18, 2025 | Volume: 37 | Issue: 1 | Pages: 96-101

10.1111/jce.70183 | PMID 41250887 Get It

ABSTRACT Background Large vegetations in cardiac implantable electronic devices (CIEDs) are associated with high mortality due to risks of major pulmonary artery obstruction. The rising incidence of CIEDs infections has complicated management, particularly in patients with delayed diagnoses. Current guidelines recommend open‐heart surgery for vegetations > 2.5 cm, but this approach poses significant risks for high‐morbidity patients. This study evaluates the feasibility and outcomes of percutaneous vacuum‐assisted aspiration using the AngioVac system in managing giant vegetations (≥ 4.0 cm) in patients unsuitable for open surgery. Materials and Methods Fourteen patients with giant vegetations (≥ 4.0 cm), undergoing transvenous lead extraction, were treated with the AngioVac system. The procedure involved large‐bore central venous cannulation and extracorporeal aspiration of vegetations. Outcomes assessed included procedural success, embolization management, and post‐extraction microbiological findings. Results The cohort included 64% males with a median age of 73 years. Vegetation sizes ranged from 4.0 to ≥ 7.0 cm. Most patients (79%) presented with advanced heart failure symptoms (NYHA class III/IV). Despite pulmonary embolism in 29% of cases, all were successfully managed with mechanical aspiration. The procedure achieved 100% complete removal of all leads and vegetations, with no perioperative mortality, and all patients were discharged alive. Conclusion Percutaneous aspiration using the AngioVac system is a safe and effective alternative to open‐heart surgery for high‐risk patients with giant vegetations. This minimally invasive approach demonstrates potential for broader application in managing high‐risk CIEDs infections, warranting further investigation in larger studies.
Influence of body mass index on cardiovascular risk in rheumatoid arthritis varies across anti-citrullinated protein antibody status and biologic use
Karpouzas, George , González‐Gay, Miguel Á. , Corrales, Alfonso, Myasoedova, Elena , Rantapää‐Dahlqvist, Solbritt , Sfikakis, Petros P. , Dessein, PH, Pascual‐Ramos, Virginia , Contreras-Yáñez, Irazú , Galarza-Delgado, D. Á. , Riel, Piet Leonardus Cornelis Maria van, Patrick, D R, Løgstrup, Brian Bridal , Hauge, Ellen‐Margrethe , Karpouzas, George Athanasios , Dessein, Patrick , Pascual-Ramos, Virginia , Colunga-Pedraza, Iris J , Galarza-Delgado, Dionicio Angel , Semb, Anne Grete , Misra, Durga Prasanna , Gonzalez-Gay, Miguel A , Myasoedova, Elena , Rantapää-Dahlqvist, Solbritt , Hitchon, Carol , Colunga-Pedraza, I. J. , Azpiri-Lopez, Jose Ramon , Semb, Anne Grete , Riel, Piet L. C. M. van , Misra, Durga Prasanna , Kitas, George D. , Ormseth, Sarah R.

Mayo Clinic

RMD Open | April 5, 2025 | Volume: 11 | Issue: 2 | Pages: e005464

10.1136/rmdopen-2025-005464 | PMID 40187772 Get It

Objectives The impact of body mass index (BMI) on cardiovascular risk in rheumatoid arthritis (RA) is unclear. RA characteristics may influence the association between BMI and risk. Disease activity, which predicts cardiovascular risk, is associated with obesity only among anticitrullinated antibody (ACPA)-positive patients. Biologics alter body composition and mitigate cardiovascular risk in RA. We explored the association of BMI with cardiovascular risk and whether this varied across ACPA status and biologic use. Methods We evaluated 3982 patients from an international observational cohort. Outcomes included (a) first major adverse cardiovascular event (MACE) encompassing myocardial infarction, stroke or cardiovascular death; and (b) all events comprising MACE, angina, revascularisation, transient ischaemic attack, peripheral arterial disease and heart failure. Multivariable Cox models stratified by centre risk evaluated the impact of BMI, ACPA, biologics and their two- and three-way interactions on outcomes. Results We recorded 192 MACE and 319 total events. No main effects of BMI, ACPA or biologics were observed. A three-way interaction between them on MACE (p-interaction<0.001) and all events (p-interaction=0.028) was noted. Among ACPA negative patients, BMI was inversely associated with MACE (HR 0.38 (95% CI 0.25 to 0.57)) and all events (HR 0.67 (0.49 to 0.92)) in biologic users but not non-users (p-for-interaction <0.001 and 0.012). Among ACPA-positive patients, BMI was associated with MACE (HR 1.04 [1.01–1.07]) and all events (HR 1.03 (1.00 to 1.06)) independently of biologic use. Conclusions BMI is inversely associated with cardiovascular risk only among ACPA-negative biologic users. In contrast, BMI is associated with cardiovascular risk in ACPA-positive patients independently of biologic use.